Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ed Schoonveld
How to prove the real – and implicit – economic value of pharma products to payers and other stakeholders while FDA regulatory approvals adhere to a historically rigid standard of proof based on randomized tests against placebo in a controlled patient population? The 21st Century Cures Act may finally be extending a new path forward that offers legislative endorsement for use of a greater variety of evidence. What the FDA decides to do on this score is emerging as a key issue for biopharma in 2017.
Economic pressures and technological advances are forcing an unprecedented transformation of the payer environment. Biopharma companies must adjust their market access and pricing strategies to maintain competitively well-positioned and profitable organizations.